These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2972594)

  • 1. Effectiveness, specificity and safety of intranasal 1-deamino-8-D-arginine vasopressin treatment of normal blood donors.
    Palmer DS; Harris AS; Tittley P; Rock G
    Haemostasis; 1988; 18(3):187-96. PubMed ID: 2972594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis].
    Köhler M; Kotitschke R; Braun B; Hellstern P; Mörsdorf S; Pindur G; Heiden M; Wenzel E
    Beitr Infusionsther; 1990; 26():136-41. PubMed ID: 1703813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility.
    Lethagen S; Harris AS; Sjörin E; Nilsson IM
    Thromb Haemost; 1987 Dec; 58(4):1033-6. PubMed ID: 3127915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII).
    Garcia VV; Silva IA; Borrasca AL
    Thromb Haemost; 1982 Aug; 48(1):91-3. PubMed ID: 6813999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP).
    Köhler M; Hellstern P; Miyashita C; von Blohn G; Wenzel E
    Thromb Haemost; 1986 Feb; 55(1):108-11. PubMed ID: 3085261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
    Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
    Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
    Mohri H; Hashimoto Y; Yamazaki E; Kanamori H; Okubo T
    Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of intranasal DDAVP on coagulation and fibrinolytic activity in normal persons.
    Nilsson IM; Mikaelsson M; Vilhardt H
    Scand J Haematol; 1982 Jul; 29(1):70-4. PubMed ID: 6812213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of DDAVP on plasma level of factor XII.
    Nenci GG; Berrettini M; De Cunto M; Agnelli G
    Br J Haematol; 1983 Jul; 54(3):489-92. PubMed ID: 6407513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryoprecipitate of intermediate purity produced in a closed thaw-siphon system from DDAVP stimulated blood donor plasma.
    Konecka G; Bykowska K; Ludwicka A; Letowska M; Wegrzynowicz Z; Sablinski J; Lopaciuk S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):565-70. PubMed ID: 1714861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal DDAVP: biological and clinical evaluation in mild factor VIII deficiency.
    Chistolini A; Dragoni F; Ferrari A; La Verde G; Arcieri R; Ege Mohamud A; Mazzucconi MG
    Haemostasis; 1991; 21(5):273-7. PubMed ID: 1806455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor.
    Muhm M; Grois N; Kier P; Stümpflen A; Kyrle P; Pabinger I; Bettelheim P; Hinterberger W; Lechner K
    Haemostasis; 1990; 20(1):15-20. PubMed ID: 2108912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of the efficacy and safety of intranasal DDAVP administered to normal blood donors.
    Palmer DS; Nair RC; Rock G
    Transfusion; 1988; 28(4):311-5. PubMed ID: 3388475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shortening of bleeding time after intranasal administration of 1-deamino-8-D-arginine vasopressin to patients with chronic uremia.
    Rydzewski A; Rowiński M; Myśliwiec M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):823-30. PubMed ID: 2436997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects.
    Takahashi H; Itoh M; Kobayashi I; Sakuragawa N; Shibata A
    Tohoku J Exp Med; 1980 Oct; 132(2):133-40. PubMed ID: 6777902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome.
    Pfueller SL; Howard MA; White JG; Menon C; Berry EW
    Thromb Haemost; 1987 Dec; 58(4):1060-3. PubMed ID: 3502198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies.
    Ghirardini A; Mariani G; Iacopino G; Tirindelli MC; Solinas S; Moretti T
    Thromb Haemost; 1987 Oct; 58(3):896-8. PubMed ID: 3124287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.